Article on BioWorld by Trista Morrison Biotech firms have long borrowed ideas from the high tech world. The venture-backed start-up business model on which the entire biotech industry is based came from high tech, and it has served both industries well despite their very different timelines and cost structures. Even so, current capital constraints have … Read More
Breaking Ground Article by K. Kimberly McCleary, about the Research Institute Without Walls. We believe in the power of systematically exploring all drugs and mechanisms for their potential against any disease. We have used this idea as the driving force to create a technologic capability, COSS, that maps and ranks all drugs versus all diseases, side … Read More
Article by Health Blog’s Amy Dockser Marcus on Biovista’s contribution to CFS research. The CFIDS Association of America says that $2 million in funding — backed by individual gifts including a $250,000 donation from best-selling writer Laura Hillenbrand, who has chronic fatigue syndrome– is going to grants and projects designed to accelerate the development of … Read More
Saving time and money The resources required to bring a new drug to market are as well-known as they are staggering: upwards of $1.3 billion in costs, 10 to 15 years from target selection to approval, and an overall failure rate approaching 95%.
By Anette Breind, BioWorld Insight For Academia or Industry In the private space, Charlottesville, Va.-based Biovista Inc…Biovista has a positioning program that uses a bioinformatics approach to “develop all reasonable opportunities” for a drug, Persidis said, by tracking “without bias,” all biological effects of a compound…But Biovista is also developing its own in-house pipeline of existing … Read More